Profile data is unavailable for this security.
About the company
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
- Revenue in USD (TTM)1.80m
- Net income in USD-7.74m
- Incorporated2002
- Employees7.00
- LocationDyadic International Inc1044 NORTH U.S. HIGHWAY ONE, SUITE 201JUPITER 33477United StatesUSA
- Phone+1 (561) 743-8333
- Fax+1 (561) 743-8343
- Websitehttps://dyadic.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acurx Pharmaceuticals Inc | 0.00 | -16.73m | 30.22m | 4.00 | -- | 8.68 | -- | -- | -1.15 | -1.15 | 0.00 | 0.2143 | 0.00 | -- | -- | 0.00 | -211.55 | -- | -346.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -35.51m | 30.78m | 15.00 | -- | -- | -- | -- | -1.30 | -1.30 | 0.00 | -0.2026 | 0.00 | -- | -- | 0.00 | -356.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Longeveron Inc | 1.23m | -27.90m | 31.59m | 23.00 | -- | 1.42 | -- | 25.70 | -8.75 | -8.75 | 0.3641 | 1.55 | 0.0674 | -- | 7.83 | 53,434.78 | -101.98 | -63.15 | -127.46 | -75.68 | 58.99 | 33.70 | -1,513.83 | -441.02 | -- | -- | 0.00 | -- | -41.98 | -19.78 | -17.92 | -- | 26.80 | -- |
| Iterum Therapeutics PLC | 0.00 | -28.34m | 31.79m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.658 | 0.00 | -- | -- | 0.00 | -86.93 | -118.12 | -150.76 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 2.06 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| SAB Biotherapeutics Inc | 2.78m | -40.32m | 32.39m | 57.00 | -- | 0.7024 | -- | 11.65 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| LianBio - ADR | 0.00 | -87.98m | 32.42m | 163.00 | -- | 0.1589 | -- | -- | -0.8195 | -0.8195 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -28.62 | -- | -35.22 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.82 | -- | -- | -- |
| FibroGen Inc | 173.82m | -168.32m | 32.43m | 486.00 | -- | -- | -- | 0.1866 | -1.71 | -1.71 | 1.76 | -2.31 | 0.4301 | 1.22 | 44.10 | 357,644.00 | -42.40 | -30.62 | -89.79 | -42.31 | 76.65 | 93.52 | -98.60 | -119.08 | 1.24 | -12.47 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Aligos Therapeutics Inc | 7.97m | -75.74m | 32.57m | 68.00 | -- | 0.9524 | -- | 4.09 | -25.99 | -25.99 | 1.89 | 10.70 | 0.0741 | -- | -- | 120,712.10 | -70.47 | -51.20 | -92.27 | -59.73 | -- | -- | -950.61 | -1,399.21 | -- | -- | 0.0031 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Surrozen Inc | 0.00 | -53.45m | 32.60m | 42.00 | -- | 5.38 | -- | -- | -21.74 | -21.74 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -98.01 | -- | -110.62 | -- | -- | -- | -- | -- | -- | -2.05 | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -64.66m | 32.83m | 41.00 | -- | 0.3336 | -- | -- | -2.26 | -2.26 | 0.00 | 3.30 | 0.00 | -- | -- | 0.00 | -62.35 | -- | -69.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Impact Biomedical Inc | 0.00 | -4.25m | 33.34m | 1.00 | -- | 1.43 | -- | -- | -0.3694 | -0.3694 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -9.59 | -- | -15.04 | -- | -- | -- | -- | -- | -- | -5.12 | 0.3377 | -- | -100.00 | -- | 38.51 | -- | -- | -- |
| Dyadic International Inc | 1.80m | -7.74m | 33.60m | 7.00 | -- | 10.61 | -- | 18.63 | -0.2675 | -0.2675 | 0.0624 | 0.1075 | 0.1662 | -- | 3.55 | 257,731.40 | -71.33 | -36.82 | -87.19 | -39.85 | 50.01 | 22.47 | -429.07 | -410.16 | -- | -- | 0.6324 | -- | -1.07 | 17.48 | 30.20 | -- | -- | -- |
| NextCure Inc | 0.00 | -61.28m | 36.09m | 82.00 | -- | 0.4224 | -- | -- | -2.20 | -2.20 | 0.00 | 3.05 | 0.00 | -- | -- | 0.00 | -47.88 | -22.59 | -51.64 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Curis Inc | 10.16m | -47.57m | 36.70m | 48.00 | -- | -- | -- | 3.61 | -8.24 | -8.24 | 1.76 | -0.1175 | 0.1509 | -- | 4.12 | 211,687.50 | -70.62 | -37.25 | -90.04 | -41.12 | 98.30 | 96.05 | -468.18 | -409.44 | -- | -- | -- | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
| Marker Therapeutics Inc | 3.73m | -10.31m | 36.94m | 8.00 | -- | 3.80 | -- | 9.91 | -1.16 | -1.17 | 0.4196 | 1.09 | 0.2217 | -- | 1.76 | 465,930.00 | -61.30 | -53.74 | -71.74 | -62.25 | -- | -- | -276.53 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Nuo Therapeutics Inc | 1.03m | -2.69m | 37.28m | -- | -- | 60.77 | -- | 36.24 | -0.0622 | -0.0622 | 0.0237 | 0.0132 | 0.7332 | 0.954 | 4.06 | -- | -191.94 | -116.16 | -381.40 | -354.84 | 79.48 | 70.02 | -261.78 | -854.53 | 1.39 | -2,383.08 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Data as of Nov 08 2024. Currency figures normalised to Dyadic International Inc's reporting currency: US Dollar USD
14.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bandera Partners LLCas of 30 Jun 2024 | 1.57m | 5.32% |
| Chapin Davis, Inc. (Investment Management)as of 30 Sep 2024 | 868.30k | 2.95% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 798.42k | 2.71% |
| Northeast Financial Consultants, Inc.as of 30 Jun 2024 | 250.00k | 0.85% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 244.40k | 0.83% |
| Geode Capital Management LLCas of 30 Jun 2024 | 238.46k | 0.81% |
| Sage Mountain Advisors LLCas of 30 Sep 2024 | 106.56k | 0.36% |
| Hightower Advisors LLCas of 30 Jun 2024 | 79.27k | 0.27% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 73.29k | 0.25% |
| Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 30 Jun 2024 | 49.97k | 0.17% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
